Thrombin generation: What have we learned?

Blood Reviews

Volumn 26, Issue 5, 2012, Pages 197-203

  Al Dieri, Raed ^a   de Laat, Bas ^a   Hemker, H Coenraad ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anticoagulation; Bleeding; Clotting system; Thrombin generation; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; ANTIVITAMIN K; DABIGATRAN; FIBRINOGEN; HEPARIN; PHOSPHOLIPID; PROTHROMBIN; RIVAROXABAN; THROMBIN; THROMBOMODULIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BRAIN ISCHEMIA; FIBRINOLYSIS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

BLOOD COAGULATION; BLOOD PLATELETS; HEMORRHAGE; HUMANS; THROMBIN; THROMBOSIS;

EID: 84865172865     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.06.001     Document Type: Article

References (125)

1. Hemker H.C., Beguin S. Phenotyping the clotting system. Thromb Haemost 2000, 84(5):747-751.
2. Baglin T. The measurement and application of thrombin generation. Br J Haematol 2005, 130:653-661.
3. van Veen J.J., Gatt A., Makris M. Thrombin generation testing in routine clinical practice: are we there yet?. Br J Haematol Sep 2008, 142(6):889-903.
4. ten Cate H. Thrombin generation in clinical conditions. Thromb Res 2012, 129(3):367-370.
5. Hemker H.C., Wielders S., Kessels H., Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993, 70:617-624.
6. Lester R.H., Elston R.C., Graham J.B. Variations in levels of blood clotting factors IX and X in a population of normal men: possible genetic polymorphisms. Am J Hum Genet 1972, 24:168-180.
7. van den Berg H.M., De Groot P.H., Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 2007, 5(Suppl. 1):151-156.
8. Siller-Matula J.M., Schwameis M., Blann A., Mannhalter C., Jilma B. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost 2011, 106:1020-1033.
9. Furie B., Furie B.C. Mechanisms of thrombus formation. N Engl J Med 2008, 359:938-939.
10. Hartert H. Blutgerinnungsstudienmit der thrombelastographie, einemneuen untersuchungsverfahren. Klin Wochenschr 1948, 26:577-583.
11. Sorensen B., Johansen P., Christiansen K., Woelke M., Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003, 1:551-558.
12. O'Donnell J., Riddell A., Owens D., et al. Role of the thrombelastograph as an adjunctive test in thrombophilia screening. Blood Coagul Fibrinolysis 2004, 15(3):207-211.
13. Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Semin Hematol 2004, 41:125-131.
14. van der Poll T., Buller H.R., ten Cate H., et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990, 322:1622-1627.
15. Kyrle P.A., Mannhalter C., Beguin S., et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998, 18(8):1287-1291.
16. Siegemund T., Petros S., Siegemund A., Scholz U., Engelmann L. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003, 90(5):781-786.
17. Kakkar V.V., Hoppenstead D.A., Fareed J., et al. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002, 99(6):1965-1970.
18. Seo J.W., Kim H.K., Kim J.E., Park S., Cho H.I. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation. Thromb Res 2009, 123:565-572.
19. Wielders S., Mukherjee M., Michiels J., et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997, 77(4):629-636.
20. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965, 13:516-530.
21. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981, 68:1370-1373.
22. Schwarz H.P., Fischer M., Hopmeier P., Batard M.A., Griffin J.H. Plasma protein S deficiency in familial thrombotic disease. Blood 1984, 64:1297-1300.
23. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88:3698-3703.
24. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
25. Dahlback B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993, 90:1004-1008.
26. Jick H., Slone D., Westerholm B., et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969, 1:539-542.
27. Uitte de Willige S., de Visser M.C., Houwing-Duistermaat J.J., Rosendaal F.R., Vos H.L., Bertina R.M. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood 2005, 106:4176-4183.
28. Duchemin J., Pittet J.L., Tartary M., et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemost 1994, 71(3):331-338.
29. Curvers J., Thomassen M.C., Rimmer J., et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002, 88(1):5-11.
30. Nicolaes G.A., Thomassen M.C., Tans G., Rosing J., Hemker H.C. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibrinolysis 1997, 8(1):28-38.
31. Rosing J., Tans G., Nicolaes G.A., et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997, 97(1):233-238.
32. Rotteveel R.C., Roozendaal K.J., Eijsman L., Hemker H.C. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 1993, 70(6):959-962.
33. Schubert L., Gibelli A., De Nicola P. Blood coagulation and fibrinolysis in patients treated with an anovulatory drug having an estroprogestational action. Ann Ostet Ginecol 1968, 90:48-58.
34. van Deijk W.A., van Dam-Mieras M.C., Muller A.D., Hemker H.C. Evaluation of a coagulation assay determining the activity state of factor VII in plasma. Haemostasis 1983, 13(3):192-197.
35. de Laat B., Mertens K., de Groot P.G. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol Apr 2008, 4(4):192-199.
36. de Laat B., Derksen R.H., Reber G., et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost Jan 2011, 9(1):149-153.
37. Devreese K., Peerlinck K., Arnout J., Hoylaerts M.F. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost Jan 2009, 101(1):185-196.
38. de Laat B., van Os G., Ninivaggi M., et al. Anti-domain I antibodies have a prothrombotic character on coagulation by inhibiting the anticoagulant effect of beta2GPI. Thromb Haemost 2011, 9(s2):290-291.
39. Regnault V., Beguin S., Wahl D., de Maistre E., Hemker H.C., Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003, 89(2):208-212.
40. Rickles F.R., Patierno S., Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 2003, 124(3 Suppl.):58S-68S.
41. Orbe J., Zudaire M., Serrano R., et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008 Feb, 99(2):382-387.
42. Falanga A., Panova-Noeva M., Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 2009, 22(1):49-60.
43. Ay C., Dunkler D., Simanek R., et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol May 20 2011, 29(15):2099-2103.
44. Ferroni P., Martini F., Portarena I., et al. An activated protein C-dependent thrombin generation assay predicts chemotherapy associated venous thromboembolism in cancer patients. Thromb Haemost May 2011, 105(5):931-932.
45. Dargaud Y., Trzeciak M.C., Bordet J.C., Ninet J., Negrier C. Use of calibrated automated thrombinography+/-thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006, 96:562-567.
46. ten Cate-Hoek A.J., Dielis A.W., Spronk H.M., et al. Thrombin generation in patients after acute deep-vein thrombosis. Thromb Haemost 2008, 100:240-245.
47. Tripodi A., Martinelli I., Chantarangkul V., Battaglioli T., Clerici M., Mannucci P.M. The endogenous thrombin potential and the risk of venous thromboembolism. Thromb Res 2007, 121:353-359.
48. van Hylckama Vlieg A., Christiansen S.C., Luddington R., Cannegieter S.C., Rosendaal F.R., Baglin T.P. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007, 138:769-774.
49. Besser M., Baglin C., Luddington R., van Hylckama Vlieg A., Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008, 6:1720-1725.
50. Tripodi A. The history of phenotypic testing in thrombosis and hemostasis. Semin Thromb Hemost 2008, 34:585-592.
51. Carcaillon L., Alhenc-Gelas M., Bejot Y., et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol 2011, 31(6):1445-1451.
52. Gast A., Tschopp T.B., Baumgartner H.R. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb 1994, 14(9):1466-1474.
53. Badimon L., Badimon J.J., Lassila R., Heras M., Chesebro J.H., Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. Blood 1991, 78(2):423-434.
54. Badimon J.J., Lettino M., Toschi V., et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999, 99(14):1780-1787.
55. Heras M., Chesebro J.H., Webster M.W., et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990, 82(4):1476-1484.
56. Ulrich-Möckel N.V., Riehle M., Vollert J., et al. Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome. Biomarkers Aug 2009, 14(5):311-316.
57. Giroud M., Dutrillaux F., Lemesle M., et al. Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different. Neurol Res 1998, 20(1):15-18.
58. Gurfinkel E., Altman R., Scazziota A., Rouvier J., Mautner B. Importance of thrombosis and thrombolysis in silent ischaemia: comparison of patients with acute myocardial infarction and unstable angina. Br Heart J 1994, 71(2):151-155.
59. Haider A.W., Andreotti F., Thompson G.R., Kluft C., Maseri A., Davies G.J. Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction. Circulation 1996, 94(9):2072-2076.
60. Martinez-Sales V., Vila V., Reganon E., et al. Elevated thrombotic activity after myocardial infarction: a 2-year follow-up study. Haemostasis 1998, 28(6):301-306.
61. Soskin P., Mossard J.M., Arbogast R., et al. Variation in von Willebrand's factor according to the treatment of acute myocardial infarction: physiopathological and clinical implications. Eur Heart J 1994, 15(4):479-482.
62. Soskin P., Wiesel M.L., Mossard J.M., et al. Potential thrombogenicity of coronary angioplasty compared with coronary angiography. Blood Coagul Fibrinolysis 1994, 5(6):965-966.
63. Tanaka M., Suzuki A. Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers. Thromb Res 1994, 76(3):289-298.
64. Faber C.G., Lodder J., Kessels F., Troost J. Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol Haemost Thromb 2003, 33(1):52-58.
65. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980, 2(8202):989-994.
66. Neri Serneri G.G., Modesti P.A., Gensini G.F., et al. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group. Lancet 1995, 345:1201-1204.
67. Neri Serneri G.G., Rovelli F., Gensini G.F., Pirelli S., Carnovali M., Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987, 1(8539):937-942.
68. Kessels H., Beguin S., Andree H., Hemker H.C. Measurement of thrombin generation in whole blood-the effect of heparin and aspirin. Thromb Haemost 1994, 72(1):78-83.
69. Musial J., Radwan J., Szczeklik A. Aspirin delays thrombin generation in vitro through interaction with platelet phospholipids. Thromb Res 1997, 85(4):367-368.
70. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996, 98(3):863-874.
71. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet 2000, 355(9212):1295-1302.
72. Panova-Noeva M., Marchetti M., Spronk H.M., et al. Platelet induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol Apr 2011, 86(4):337-342.
73. With Noto A.T., Mathiesen E.B., Osterud B., Amiral J., Vissac A.M., Hansen J.B. Increased thrombin generation in persons with echogenic carotid plaques. Thromb Haemost 2008, 99(3):602-608.
74. Peyvandi F., Mannucci P.M. Rare coagulation disorders. Thromb Haemost 1999, 82(4):1207-1214.
75. Gilmore R., Harmon S., Gannon C., Byrne M., O'Donnell J.S., Jenkins P.V. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia 2010, 16:671-674.
76. Santagostino E., Mancuso M.E., Tripodi A., et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010, 8:737-743.
77. van Veen J.J., Gatt A., Bowyer A.E., Cooper P.C., Kitchen S., Makris M. Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. Thromb Res 2009, 123:895-901.
78. Gatt A., van Veen J.J., Woolley A.M., Kitchen S., Cooper P., Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008, 100:350-355.
79. van Veen J.J., Gatt A., Bowyer A.E., Cooper P.C., Kitchen S., Makris M. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. Int J Lab Hematol 2009, 31:189-198.
80. Trossaert M., Regnault V., Sigaud M., Boisseau P., Fressinaud E., Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost 2008, 6:486-493.
81. Lewis S.J., Stephens E., Florou G., et al. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion. Br J Haematol 2007, 138:775-782.
82. Beltran-Miranda C.P., Khan A., Jaloma-Cruz A.R., Laffan M.A. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005, 11:326-334.
83. Dargaud Y., Beguin S., Lienhart A., et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005, 93:475-480.
84. Siegemund T., Petros S., Siegemund A., Scholz U., Engelmann L. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003, 90:781-786.
85. Chantarangkul V., Clerici M., Bressi C., Giesen P.L., Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003, 88:547-554.
86. Jayandharan G.R., Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008, 34(1):128-141.
87. van Dijk K., van der Bom J.G., Fischer K., Grobbee D.E., van den Berg H.M. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004, 92:305-310.
88. van Dijk K., van der Bom J.G., Fischer K., de Groot P.G., van den Berg H.M. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost 2007, 5:1062-1064.
89. Ninivaggi M., Dargaud Y., van Oerle R., de Laat B., Hemker H.C., Lindhout T. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A. J Thromb Haemost 2011, 9:1549-1555.
90. Al Dieri R., Peyvandi F., Santagostino E., et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002, 88(4):576-582.
91. Keularts I.M., Zivelin A., Seligsohn U., Hemker H.C., Beguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001, 85(6):1060-1065.
92. Dargaud Y., Beguin S., Lienhart A., et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005, 93(3):475-480.
93. Azar A.J., Cannegieter S.C., Deckers J.W., et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996, 27:1349-1355.
94. Keularts I.M., Hamulyak K., Hemker H.C., Beguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost 2000, 84(4):638-642.
95. Dargaud Y., Lienhart A., Meunier S., et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005, 11(5):552-558.
96. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol 2004, 41(1 Suppl. 1):35-39.
97. Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol 2006, 43(1 Suppl. 1):S105-S107.
98. Turecek P.L., Varadi K., Keil B., et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003, 33(1):16-22.
99. Turecek P.L., Varadi K., Schwarz H.P. Update on the mechanism of action and future of activated prothrombin complex concentrates. Curr Hematol Rep 2004, 3(5):331-337.
100. Luporsi P., Chopard R., Janin S., et al. Use of recombinant factor VIIa (NovoSeven) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Card Care 2011, 13(2):93-98.
101. Beguin S., Keularts I., Al Dieri R., Bellucci S., Caen J., Hemker H.C. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. J Thromb Haemost 2004, 2(1):170-176.
102. Beguin S., Kumar R., Keularts I., Seligsohn U., Coller B.S., Hemker H.C. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999, 93(2):564-570.
103. Lisman T., Mosnier L.O., Lambert T., et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002, 99(1):175-179.
104. Lee A.P., Boyle C.A., Savidge G.F., Fiske J. Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. Br Dent J 2005, 198(1):33-38. (discussion 26).
105. Gulseth M.P., Michaud J., Nutescu E.A. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health Syst Pharm 2008, 65(16):1520-1529.
106. Perzborn E., Kubitza D., Misselwitz F. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie 2007, 27(4):282-289.
107. Graff J., von Hentig N., Misselwitz F., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007, 47(11):1398-1407.
108. Borris L.C. Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty. Expert Opin Pharmacother 2009, 10(6):1083-1088.
109. Green L., Lawrie A.S., Patel R., et al. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters. Thromb Res 2012, 10.1016/j.thromres.2011.12.023.
110. Serebruany V., Sani Y., Lynch D., et al. Effects of dabigatran in vitro on thrombin biomarkers by calibrated automated thrombography in patients after ischemic stroke. J Thromb Thrombolysis 2011, 33:22-27.
111. Freyburger G., Macouillard G., Labrouche S., Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011, 127:457-465.
112. Ammollo C.T., Semeraro F., Incampo F., Semeraro N., Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010, 8:790-798.
113. Stangier J., Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009, 15(Suppl. 1):9S-16S.
114. Wienen W., Stassen J.M., Priepke H., Ries U.J., Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007, 98:155-162.
115. Wagenvoord R.J., Deinum J., Elg M., Hemker H.C. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin. J Thromb Haemost 2010, 8(6):1281-1289.
116. Furugohri T., Sugiyama N., Morishima Y., Shibano T. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost 2011, 106(6):1076-1083.
117. Hemker H.C., Giesen P., Al Dieri R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33(1):4-15.
118. Al Dieri R., Wagenvoord R., van Dedem G.W., Beguin S., Hemker H.C. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif-the C-domain. J Thromb Haemost 2003, 1(5):907-914.
119. Hron G., Kollars M., Binder B.R., Eichinger S., Kyrle P.A. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006, 296(4):397-402.
120. Al Dieri R., Beguin S., Hemker H.C. The ionic contrast medium ioxaglate interferes with thrombin-mediated feedback activation of factor V, factor VIII and platelets. J Thromb Haemost 2003, 1(2):269-274.
121. Herault J.P., Dol F., Gaich C., Bernat A., Herbert J.M. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost 1999, 81(6):957-960.
122. Hackeng T.M., Seré K.M., Tans G., Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. PNAS 2006, 103(9):3106-3111.
123. Calatzis A., Reininger A., Spannagl M., Schramm W. Rapid and automated quantification of the kinetics of thrombin formation using the thrombin dynamics test (TDT). J Thromb Haemost 2003, 1:1589. (abstract).
124. Hemker H.C., Giesen P.L., Ramjee M., Wagenvoord R., Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000, 83(4):589-591.
125. De Smedt E., Hemker H.C. Thrombin generation is extremely sensitive to preheating conditions. J Thromb Haemost 2010, 9(1):233-234.